NEWARK, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY. The presentation will begin at 10:30 a.m. Eastern Time on Wednesday, February 27, 2019.
A live audio webcast of the presentation can be accessed through the Investors section of the CymaBay Therapeutics corporate website at http://ir.cymabay.com/events. The webcast will be archived on the corporate website for 90 days.
About CymaBay CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chroni diseases with high unmet medical need. CymaBay’s lead development candidate, seladelpar, is a potent, selective and orally active PPARd agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently enrolling patients in a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placEbo-coNtrolled, randomized, pHAse 3 study to evaluate the safety aNd effiCacy of sEladelpar (ENHANCE) in patients with PBC. Seladelpar received orphan designation from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for PBC. Seladelpar also received Breakthrough Therapy Designation from the FDA and PRIority MEdicine status from the EMA for PBC. CymaBay is also conducting a Phase 2b proof-of-concept study of seladelpar for patients with NASH.
For additional information about CymaBay visit www.cymabay.com.
Contact: Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
